Anticancer activity of a lectin-rich mistletoe extract injected intratumorally into human pancreatic cancer xenografts

Anticancer Research

Volumn 25, Issue 3 B, 2005, Pages 1969-1975

  Rostock, Matthias ^a,b   Huber, R ^a   Greiner, T ^c   Fritz, P ^d   Scheer, R ^e   Schueler, J ^c   Fiebig, H H ^c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c CHARLES RIVER LABORATORIES   (United States)

^d ROBERT BOSCH GMBH   (Germany)

^e ABNOBA GMBH   (Germany)

Author keywords

Antitumour activity; Gemcitabine; Human cancer xenograft; Intratumoral injection; Mistletoe extract; Mistletoe lectin; Pancreatic cancer; Viscum album

Indexed keywords

GEMCITABINE; LECTIN; VISCUM ALBUM EXTRACT;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER REGRESSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG ISOLATION; HUMAN; INJECTION; INOPERABLE CANCER; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT; VISCUM ALBUM;

ADENOCARCINOMA; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; PLANT PREPARATIONS; PLANT PROTEINS; REMISSION INDUCTION; TOXINS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 21344472990     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Evans DB, Abbruzzese JL and Willett CG: Cancer of the pancreas. In: Cancer Principles & Practice of Oncology (DeVita VT Jr, Hellman S, Rosenberg SA eds). New York, NY, Lippincott Williams & Wilkins, pp. 1126-1161, 2001.
2. Abbruzzese JL: Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality. Semin Oncol 29(Suppl 20): 2-8, 2002.
3. Heinemann V: Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials. Semin Oncol 29(Suppl 20): 9-16, 2002.
4. Kienle GS and Kiene H: Die Mistel in der Onkologie. Stuttgart, Schattauer Verlag, 2003.
5. Franz H: Mistletoe lectins and their A and B chains. Oncology 43: 23-34, 1986.
6. Janssen O, Scheffler A and Kabelitz D: In vitro effects of mistletoe extracts and mistletoe lectins. Cytotoxicity towards tumour cells due to the induction of programmed cell death (apoptosis). Drug Res 43: 1221-1227, 1993.
7. Bussing A and Schietzel M: Apoptosis-inducing properties of Viscum album L. extracts from different host trees correlate with their content of toxic mistletoe lectins. Anticancer Res 19: 23-28, 1999.
8. Nabrotzki M and Scheffler A: Komplette Remission nach intratumoraler Misteltherapie eines Duodenum-Karzinom-Rezidivs. In: Die Mistel in der Tumortherapie, Grundlagenforschung und Klinik (Scheer R, Bauer R, Becker H, Berg PA, Fintelmann V, eds). Essen, KVC Verlag, pp. 413-422, 2001.
9. Drees M, Berger DP, Dengler WA and Fiebig HH: Direct cytotoxic effects of preparations used as unconventional methods in cancer therapy in human tumor xenografts in the clonogenic assay and in nude mice. In: Immunodeficient Animals: Models for Cancer Research (Arnold W, Köpf-Maier P, Micheel B, eds). Basel, Karger Verlag, pp. 115-122, 1996.
10. Scheer R: Sicherung der pharmazeutischen Qualität von Mistelpräparaten. In: Grundlagen der Misteltherapie (Scheer R, Becker H, Berg PA, eds). Stuttgart, Hippokrates Verlag, pp. 139-150, 1996.
11. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J et al [United Kingdom Coordinating Committee on Cancer Research (UKCCCR)]: Guidelines for the welfare of animals in experimental neoplasia, 2nd ed. Br J Cancer 77: 1-10, 1998.
12. Fiebig HH, Dengler WA and Roth T: Human tumor xenografts: predictivity, characterization and discovery of new anticancer agents. In: Relevance of Tumor Models for Anticancer Drug Development (Fiebig HH and Burger AM). Contrib Oncol 54: 29-50, 1999.
13. Boven E, Winograd B, Berger DP, Dumont MP, Braakhuis BJ, Fodstad O, Langdon S and Fiebig HH: Phase II preclinical drug screening in human tumour xenografts: a first European multicenter collaborative study. Cancer Res 52: 5940-5947, 1992.
14. Mengs U, Schwarz T, Bulitta M and Weber K: Antitumoural effects of an intravesically applied aqueous mistletoe extract on urinary bladder carcinoma MB49 in mice. Anticancer Res 20: 3565-3568, 2000.
15. Elsässer-Beile U, Ruhnau T, Freudenberg N, Wetterauer U and Mengs U: Antitumoural effect of recombinant mistletoe lectin on chemically induced urinary bladder carcinogenesis in a rat model. Cancer 91: 998-1004, 2001.
16. Berg PA and Stein GM: Does mistletoe therapy influence the defense against epithelial tumours? A critical immunological analysis. Dtsch Med Wschr 126: 339-345, 2001.
17. Bussing A (ed): Mistletoe. The Genus Viscum. Amsterdam, Hardwood Academic Publishers, 2000.
18. Stumpf C, Ramirez-Martinez S, Becher A, Stein GM, Bussing A and Schietzel M: Intratumorale Mistelapplikation bei stenosierendem Rezidiv eines Cardia-Carzinoms. Erfahrungsheilkunde 46: 509-513, 1997.
19. Matthes H: Intraläsionale Mistelinjektionen in Lebermetastasen bei kolorektalem Karzinom und in das primäre Hepatozelluläre Karzinom (HCC) [Abstract]. Merkurstab 50: 41, 1997.